Synerkine Pharma BV secures EUR 12.1m in Series A extension
Dutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01.
The Series A extension was led by Flerie with participation of existing investor Thuja Capital and new investors InnovationQuarter Capital and Utrecht Health Seed Fund. Complementing the Series A extension, Synerkine has received a matching RVO Innovation Credit from the Netherlands Enterprise Agency.
The proceeds of €12.1m will be used to advance Synerkines cytokine fusion protein SK-01 into clinical studies in complex regional pain syndrome (CRPS), a severe chronic pain indication. The companys proprietary Synerkine SK-01 combine the two biologically relevant and synergistic anti-inflammatory cytokines IL-4 and IL-10 reverse the state of central sensitisation, holding the potential to fully reverse chronic pain.
Synerkine Pharma B.V. focuses on the development of Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.
